This inventor holds 1 USPTO granted patent and 8 published patent applications, plus 1 CIPO patent. Top assignee: Abbvie Inc.. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Innovations by Jose Jeffrey V Enejosa in Treating Crohn's Disease
Introduction
Jose Jeffrey V Enejosa is an innovative inventor based in Chicago, IL (US). He has made significant contributions to the medical field, particularly in the treatment of inflammatory bowel diseases. His work focuses on developing methods that improve the quality of life for patients suffering from Crohn's disease and ulcerative colitis.
Latest Patents
Jose Jeffrey V Enejosa holds 1 patent for his groundbreaking work titled "Methods of treating Crohn's disease and ulcerative colitis." This patent outlines methods for inducing clinical remission and endoscopic improvement of Crohn's disease using a JAK1 inhibitor. The innovative approach involves administering an induction dose of the JAK1 inhibitor, followed by maintenance doses to sustain the treatment's effectiveness. Additionally, the patent also addresses methods for treating ulcerative colitis with the same JAK1 inhibitor.
Career Highlights
Jose Jeffrey V Enejosa is currently associated with AbbVie Inc., a leading biopharmaceutical company. His role at AbbVie allows him to collaborate with other experts in the field and contribute to the advancement of medical treatments. His dedication to research and innovation has positioned him as a valuable asset in the medical community.
Collaborations
Some of his notable coworkers include Ana Paula Machado De Lacerda and Aileen L Pangan. Their collaborative efforts enhance the research environment and foster innovative solutions in treating complex medical conditions.
Conclusion
Jose Jeffrey V Enejosa's contributions to the treatment of Crohn's disease and ulcerative colitis exemplify the impact of innovation in medicine. His work not only advances scientific understanding but also offers hope to patients seeking effective treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile